Here’s What Raymond James Says About Spyre Therapeutics Inc (SYRE)

Spyre Therapeutics Inc (NASDAQ:SYRE) is among the best 52-week high US stocks to buy. On April 16, Spyre Therapeutics Inc (NASDAQ:SYRE) said in a press release that it raised around $463.5 million in gross proceeds from its recent equity offering. The company offered 7.48 million shares of its common stock, and granted the underwriters the option to purchase an additional 975,000 shares. The underwriters fully exercised their option. The shares were offered at a price of $62 apiece, near the 52-week high.

Here’s What Raymond James Says About Spyre Therapeutics Inc (SYRE)

Looker_Studio/Shutterstock.com

Notably, Spyre’s equity raise adds to a solid cash position. At the end of 2025, Spyre had $757 million of cash, cash equivalents, and marketable securities. The company estimated that this cash would be enough to fund its operations into the second half of 2028.

On April 13, Raymond James launched coverage of Spyre Therapeutics Inc (NASDAQ:SYRE) stock with a Strong Buy rating and a price target of $80. The firm pointed to the potential of Spyre’s clinical programs for its bullish view on the stock.

Spyre is developing next-generation, long-acting antibodies for inflammatory bowel disease and rheumatic diseases. The company says that around 2.4 million individuals in the US are diagnosed with inflammatory bowel disease. It says that more than 3 million people in the US are affected by rheumatic conditions.

Spyre has a pair of Phase 2 clinical trials in progress. Raymond James noted that proof-of-concept data readouts from these studies are expected in 2026 and 2027.

Spyre Therapeutics Inc (NASDAQ:SYRE) is a US biotechnology company based in Waltham, Massachusetts. The company is focused on developing medicines for people living with inflammatory bowel disease and rheumatic diseases. It develops advanced antibodies engineered for prolonged activity and formulated for delivery as monotherapies.

While we acknowledge the risk and potential of SYRE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SYRE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 9 Must-Buy Penny Stocks to Invest In Now and 10 Best AI Stocks to Buy Under $25.

Disclosure: None. Follow Insider Monkey on Google News.